Form 4: Dexcom Executive Sadie Stern Sells Shares Under 10b5-1 Plan

EVP and Chief Human Resources Officer of Dexcom Inc., Sadie Stern, sold 4,137 shares of common stock on March 25, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Sadie Stern, EVP and Chief Human Resources Officer at Dexcom Inc., sold 4,137 shares of common stock on March 25, 2024.
• The sale was executed under a 10b5-1 trading plan adopted on December 15, 2022, and amended on December 12, 2023.
• The price per share was $140.
• Following the transaction, Ms. Stern beneficially owns 76,304 shares of Dexcom Inc.
• This total includes 53,995 unvested restricted stock units (RSUs) granted on various dates between November 19, 2020, and March 8, 2024, vesting through November 19, 2024, and March 8, 2027.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine stock sale by an executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about the transaction.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies and are often conducted under pre-arranged trading plans like the 10b5-1 plan to avoid accusations of insider trading. These sales can be influenced by personal financial planning or diversification strategies.

Comparison to Industry Standards

• Executive compensation packages in the medical device industry often include stock options and restricted stock units (RSUs) as incentives.
• The vesting schedules for RSUs, such as those held by Ms. Stern, are typical for retaining key personnel over a multi-year period.
• Sales under 10b5-1 plans are a standard practice among executives to manage their stock holdings in a compliant manner.

Stakeholder Impact

• The stock sale by an executive could have a minor impact on shareholder sentiment, but is unlikely to significantly affect the company's operations or financial performance.

Key Dates